Company profile
KYMERA THERAPEUTICS, INC.
NASDAQ:KYMRBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TIPASERTIDEG | phase1 | — | 3 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07677059 | phase2 | recruiting | 2026-06-25 | 2028-12-01 | Kymera Therapeutics, Inc. | A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study |
| NCT04772885 | phase1 | completed | 2021-02-23 | 2022-10-20 | Kymera Therapeutics, Inc. | A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS) |
| NCT07323654 | phase2 | recruiting | 2026-01-28 | 2027-12-01 | Kymera Therapeutics, Inc. | A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma |
| NCT07217015 | phase2 | active_not_recruiting | 2025-11-24 | 2027-06-01 | Kymera Therapeutics, Inc. | A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis |
| NCT07823205 | phase1 | recruiting | 2026-10-01 | 2027-04-01 | Kymera Therapeutics, Inc. | A Study to Evaluate Different Oral Formulations of KT-621 |
FDA applications (0)
No records yet.